Daiichi Sankyo Announces Reorganization of R&D Structure

Tokyo, Japan - (January 12, 2022) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has decided to close the offices of its research and development subsidiary, Plexxikon Inc. (hereafter, Plexxikon), based in South San Francisco, California, to maximize its R&D investment in the three antibody-drug conjugates (3ADCs) of ENHERTU®, Dato-DXd, and HER3-DXd. Daiichi Sankyo has positioned the “maximize 3ADCs” as one of the strategic pillars of its 5-year Business Plan (FY2021–FY2025).

Plexxikon, with approximately 60 employees, has been engaged in research and development in oncology and neurology since 2001, and as a part of Daiichi Sankyo since 2011, with a portfolio that includes two marketed drugs Zelboraf® and Turalio®. The existing R&D pipeline at Plexxikon will be transferred to the Daiichi Sankyo Group. Plexxikon will be operational until March 31, 2022 and continue as a legal entity for the time being.

About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical need. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.

Press Release

Daiichi Sankyo Announces Reorganization of R&D Structure

Tokyo, Japan - (January 12, 2022) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has decided to close the offices of its research and development subsidiary, Plexxikon Inc. (hereafter, Plexxikon), based in South San Francisco, California, to maximize its R&D investment in the three antibody-drug conjugates (3ADCs) of ENHERTU®, Dato-DXd, and HER3-DXd. Daiichi Sankyo has positioned the “maximize 3ADCs” as one of the strategic pillars of its 5-year Business Plan (FY2021–FY2025).

Plexxikon, with approximately 60 employees, has been engaged in research and development in oncology and neurology since 2001, and as a part of Daiichi Sankyo since 2011, with a portfolio that includes two marketed drugs Zelboraf® and Turalio®. The existing R&D pipeline at Plexxikon will be transferred to the Daiichi Sankyo Group. Plexxikon will be operational until March 31, 2022 and continue as a legal entity for the time being.

About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical need. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.

Media Contacts:
Japan:
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp